Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 19/20 | 1.00 |
| ▸ | BRAF | P15056 | 2/20 | 0.69 |
| ▸ | AURKA | O14965 | 1/20 | 0.69 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.69 |
| ▸ | KIT | P10721 | 1/20 | 0.69 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.69 |
| ▸ | FLT1 | P17948 | 1/20 | 0.69 |
| ▸ | TEK | Q02763 | 1/20 | 0.69 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.69 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.63 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.63 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.62 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.62 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.62 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4286014 | 0.90 | KDR (0.82) | KDRBRAFAURKAPDGFRBKIT | |
| SCHEMBL4285054 | 0.88 | KDR (1.00) | KDRBRAFAURKAPDGFRBKIT | |
| SCHEMBL4279838 | 0.86 | KDR (1.00) | KDRBRAFAURKAPDGFRBKIT | |
| Hydrochloric Acid SCHEMBL4282868 | 0.85 | KDR (0.98) | KDRBRAFAURKAPDGFRBKIT | |
| SCHEMBL4279827 | 0.85 | KDR (0.74) | KDRBRAFAURKAPDGFRBKIT | |
| SCHEMBL4278504 | 0.83 | KDR (0.94) | KDRBRAFAURKAPDGFRBKIT | |
| SCHEMBL4287136 | 0.83 | KDR (0.71) | KDRBRAFAURKAPDGFRBKIT | |
| SCHEMBL4291131 | 0.82 | KDR (1.00) | KDRBRAFAURKAPDGFRBKIT | |
| SCHEMBL4282323 | 0.82 | KDR (0.84) | KDRBRAFAURKAPDGFRBKIT | |
| SCHEMBL4282055 | 0.82 | KDR (1.00) | KDRBRAFAURKAPDGFRBKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TIE1, KDR, FLT1 | KDR 2/4885BRAF 210/4885AURKA 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.